AWH - Aspira Women's Health Establishes a New Clinical Advisory Board | Benzinga
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or "the Company") (NASDAQ:AWH), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced it has established a Clinical Advisory Board as an element of its overall mission to develop and distribute high-impact diagnostic tools for gynecologic disease.
The Clinical Advisory Board will provide clinical input and guidance throughout the development of the Company's portfolio of products. Each member of the board is a recognized thought-leader with deep clinical expertise in gynecologic health.
"We are thrilled to have attracted this accomplished group of thought-leaders to support our mission of transforming health outcomes for women through the development and commercialization of noninvasive tests for the identification of gynecologic disease," said Nicole Sandford, President and CEO of Aspira Women's Health. "With the creation of the Clinical Advisory Board, we are able to maximize the impact of expert clinicians who believe in the potential of our technology. The Board will complement our well-established KOL network as we drive both innovation and adoption."
Dr. Leo Twiggs, Director of Medical Affairs at Aspira Women's Health added, "I am honored to have such an elite group of clinical experts advising our company in our research and product development endeavors. I look forward to working with these clinicians as we lead the mission to improve the standard of care for all women."
The Clinical Advisory Board, which will be chaired by Dr. Twiggs, includes the following initial members:
Levi S. Downs, Jr., M.D., M.S., Medical Director for Gynecologic Oncology, Park Nicollet Health System, Methodist Hospital
Dr. Downs is Director of Gynecologic Oncology at Park Nicollet Health Services in Minneapolis, MN. Dr. Downs received his medical degree from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. He did his residency in Obstetrics and Gynecology at Magee-Women's Hospital of the University of Pittsburgh Medical Center. Dr. Downs completed a fellowship in gynecologic oncology at the University of Minnesota and has a Master of Science degree in clinical research from the University of Minnesota School of Public Health. Prior to joining Park Nicollet, he was Professor of Obstetrics, Gynecology and Women's Health at the University of Minnesota Medical School where he served as Division Director for Gynecologic Oncology, Women's Cancer Program Director at the Masonic Cancer Center, and Chief Medical Officer of the University of Minnesota Medical Center and University of Minnesota Physicians. Dr. Downs has served as principal investigator for numerous clinical trials investigating cervical cancer screening, diagnosis, treatment, and preventive approaches to HPV related diseases. As an active member of the American Society for Colposcopy and Cervical Pathology (ASCCP) he has participated in cervical cancer screening and management consensus conferences. He has served on the ASCCP Board and joined the Executive Committee in 2019 and is the current ASCCP President. Dr. Downs is also a member of the Society of Gynecologic Oncologists and has served as a member on the Board of Directors of many other professional societies. He has a commitment to service ...